Humoral immune response against hepatitis C virus

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 125-127

  Burioni, Roberto ^a   Mancini, N ^b   Canducci, F ^b   Carletti, S ^b   Grieco, A ^a   Perotti, M ^a   Serafini, G ^a   Berardinelli, E ^a   Bighi, S ^a   Varaldo, P E ^a   Clementi, M ^b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Hepatitis C virus; Human monoclonal antibodies

Indexed keywords

BIOLOGICAL MARKER; CROSS REACTING ANTIBODY; VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ARTICLE; HEPATITIS C VIRUS; HEPATITIS NON A NON B; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; PERSISTENT INFECTION; VIRUS CELL INTERACTION;

HEPATITIS C VIRUS; NON-A, NON-B HEPATITIS VIRUS; RNA VIRUSES;

EID: 12444311292     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2: 706-13.
2. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135-40.
3. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388-90.
4. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody- mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792-6.
5. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 1995; 208: 653-61.
6. Piazza M, Sagliocca L, Tosone G, et al. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 1997; 157: 1537-44.
7. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin (see comments). N Engl J Med 1994; 331: 1607-11.
8. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-44.
9. Manzin A, Solforosi L, Debiaggi M, et al. Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J Virol 2000; 74: 4327-34.
10. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-41.
11. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-8.
12. Ishii K, Rosa D, Watanabe Y, et al. High titers of anti-bodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 1998; 28: 1117-20.
13. Ahmed M, Shikata T, Esumi M. Murine humoral immune response against recombinant structural proteins of hepatitis C virus distinct from those of patients. Microbiol Immunol 1996; 40: 169-76.
14. Chanock RM, Crowe JE Jr., Murphy BR, et al. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases. Infect Agents Dis 1993; 2: 118-31.
15. Plaisant P, Burioni R, Manzin A, et al. Human monoclonal recombinant Fabs specific for HCV antigens obtained by repertoire cloning in phage display combinatorial vectors. Res Virol 1997; 148: 165-9.
16. Burioni R, Plaisant P, Manzin A, et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 1998; 28: 810-4.
17. Burioni R, Bugli F, Mancini N, et al. Non-neutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 2001; 288: 29-35.
18. Bugli F, Mancini N, Kang CY, et al. Mapping B cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol 2001; 75: 9986-90.
19. Matsuura Y, Tani H, Suzuki K, et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 2001; 286: 263-75.
20. Burioni R, Matsuura Y, Mancini N, et al. Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype. J Virol 2002; 76: 11775-9.
21. Parren PW, Fisicaro P, Labrijn AF, et al. In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope. J Virol 1996; 70: 9046-50.